Becton, Dickinson and Company is involved in a stockholder derivative litigation concerning allegations against its officers and directors. The claims suggest that the individual defendants did not fulfill their fiduciary duties by making false and misleading statements regarding the Alaris infusion pump system between November 5, 2019, and February 5, 2020. A proposed settlement has been reached, and if approved by the court, current BD stockholders will be barred from contesting the approval. This settlement follows mediation in a related federal securities class action, with a hearing initially set for August 2023, which was adjourned for mediation. The proceedings are taking place in the U.S. District Court for the District of New Jersey.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.